90 related articles for article (PubMed ID: 35795500)
1. Fatal Gets More Fatal: A COVID-19 Infection With Macrophage Activation Syndrome.
Aydin Y; Vemuri B; Vajta Gomez JP; Challa PK; Zhang H
Cureus; 2022 Jun; 14(6):e25591. PubMed ID: 35795500
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
3. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
[TBL] [Abstract][Full Text] [Related]
4. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Soy M; Keser G; Atagündüz P; Tabak F; Atagündüz I; Kayhan S
Clin Rheumatol; 2020 Jul; 39(7):2085-2094. PubMed ID: 32474885
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Yongzhi X
Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
[TBL] [Abstract][Full Text] [Related]
8. Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.
Sansone NMS; Boschiero MN; Ortega MM; Ribeiro IA; Peixoto AO; Mendes RT; Marson FAL
Lancet Reg Health Am; 2022 Apr; 8():100177. PubMed ID: 35018359
[TBL] [Abstract][Full Text] [Related]
9. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.
Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P
Front Immunol; 2021; 12():589095. PubMed ID: 33995341
[TBL] [Abstract][Full Text] [Related]
10. Hypoxemia and Cytokine Storm in COVID-19: Clinical Implications.
Machado C; González-Quevedo A
MEDICC Rev; 2021; 23(3-4):54-59. PubMed ID: 34516537
[TBL] [Abstract][Full Text] [Related]
11. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Lanzoni G; Linetsky E; Correa D; Alvarez RA; Marttos A; Hirani K; Cayetano SM; Castro JG; Paidas MJ; Efantis Potter J; Xu X; Glassberg M; Tan J; Patel AN; Goldstein B; Kenyon NS; Baidal D; Alejandro R; Vianna R; Ruiz P; Caplan AI; Ricordi C
CellR4 Repair Replace Regen Reprogram; 2020; 8():. PubMed ID: 34164564
[TBL] [Abstract][Full Text] [Related]
12. Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.
Chen S; Zhang C; Chen D; Dong L; Chang T; Tang ZH
Front Immunol; 2023; 14():1200289. PubMed ID: 37483597
[TBL] [Abstract][Full Text] [Related]
13. COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review).
Krynytska I; Marushchak M; Birchenko I; Dovgalyuk A; Tokarskyy O
Iran J Microbiol; 2021 Dec; 13(6):737-747. PubMed ID: 35222850
[TBL] [Abstract][Full Text] [Related]
14. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS.
Lupu L; Palmer A; Huber-Lang M
Front Immunol; 2020; 11():584514. PubMed ID: 33101314
[TBL] [Abstract][Full Text] [Related]
15. A Case of Delayed COVID-19-Related Macrophage Activation Syndrome.
Abdelgabar A; Elsayed M
J Med Cases; 2022 May; 13(5):207-211. PubMed ID: 35655624
[TBL] [Abstract][Full Text] [Related]
16. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T
Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563
[TBL] [Abstract][Full Text] [Related]
17. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
18. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.
Convertino I; Tuccori M; Ferraro S; Valdiserra G; Cappello E; Focosi D; Blandizzi C
Crit Care; 2020 Jun; 24(1):331. PubMed ID: 32527304
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
20. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
